glutamic acid has been researched along with Dyskinesia Syndromes in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.69) | 18.7374 |
| 1990's | 7 (17.95) | 18.2507 |
| 2000's | 14 (35.90) | 29.6817 |
| 2010's | 13 (33.33) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Kalita, J; Kumar, S; Kumar, V; Misra, UK | 1 |
| Kalita, J; Kumar, V; Misra, UK; Parashar, V | 1 |
| Burris, JE; Choi, IY; Cirstea, CM; Craciunas, SC; Lee, P; Nudo, RJ | 1 |
| Morioka, H; Nishio, R; Takeda, A; Takeuchi, A; Tamano, H | 1 |
| Cadioli, M; Cariati, M; Demartini, B; Ferrucci, R; Gambini, O; Goeta, D; Marceglia, S; Priori, A; Uggetti, C | 1 |
| Conn, PJ; Moehle, MS | 1 |
| Iwata, K; Kitagawa, J; Mostafeezur, RM; Shinoda, M; Takahashi, K; Takatsuji, H; Unno, S; Yamada, Y; Yamamura, K; Zakir, HM | 1 |
| Itano, T; Keep, RF; Liu, Y; Nakamura, T; Shinomiya, A; Tamiya, T; Tokuda, M; Toyoshima, T | 1 |
| Lamont, MG; Weber, JT | 1 |
| Auvergnon, N; Benetollo, C; Cavagna, S; Giraudon, P; Malleret, G; Marignier, R; Nicole, A; Parrot, S; Peyron, C; Ruiz, A; Touret, M; Vukusic, S; Watrin, C | 1 |
| Candelario-Jalil, E; de Oliveira, AC; Fiebich, BL; Saliba, SW; Santos, RP; Teixeira, AL; Vieira, EL; Vieira, LB | 1 |
| Banaie, M; Gharibzadeh, S; Sarbaz, Y; Towhidkhah, F | 1 |
| Bernardi, G; Cantarella, C; Cavasinni, F; Centonze, D; De Chiara, V; Furlan, R; Lo Giudice, T; Martino, G; Martorana, A; Mataluni, G; Musella, A; Muzio, L; Rossi, S | 1 |
| Böhmer, AE; Elisabetsky, E; Paniz, L; Portela, LV; Schallenberger, C; Schmidt, AP; Souza, DO; Wofchuk, ST | 1 |
| Capo, TR; Carlson, SL; Fieber, LA; Schmale, MC | 1 |
| Aldinger, KA; Ashwood, P; Bauman, ML; Blaha, CD; Blatt, GJ; Chauhan, A; Chauhan, V; Dager, SR; Dickson, PE; Estes, AM; Fatemi, SH; Goldowitz, D; Heck, DH; Kemper, TL; King, BH; Martin, LA; Millen, KJ; Mittleman, G; Mosconi, MW; Persico, AM; Sweeney, JA; Webb, SJ; Welsh, JP | 1 |
| Emionite, L; Ikehata, M; Musante, I; Pittaluga, A; Puliti, A; Rastaldi, MP; Ravazzolo, R; Rossi, PI; Summa, M | 1 |
| Banczerowski-Pelyhe, I; Gulyás-Kovács, A; Takács, J; Tarnawa, I; Világi, I | 1 |
| Becker, H; Blin, O; Micallef, J; Tardieu, S | 1 |
| Archer, T; Beninger, RJ; Kostrzewa, RM; Palomo, T | 1 |
| Enyu, L; Hongmin, B; Xiang, Z; Zhou, F | 1 |
| Erb, M; Ethofer, T; Grodd, W; Kardatzki, B; Klose, U; Kraft, E; Landwehrmeyer, GB; Seeger, U; Storch, A | 1 |
| Baunez, C; Bernardi, G; Calabresi, P; Centonze, D; Gubellini, P; Picconi, B; Pisani, A; Rossi, S | 1 |
| Baker, D; Cabranes, A; de Lago, E; Fernández-Ruiz, J; López-Rodríguez, M; Ortega-Gutiérrez, S; Pryce, G; Ramos, JA | 1 |
| Fernández-Ruiz, J; Gonzáles, S | 1 |
| Alferova, VP; Barkhatova, VP; Niiazbekova, AS; Panteleeva, EA; Rebrova, OIu; Zavalishin, IA | 1 |
| Keilhoff, G; Wolf, G | 1 |
| Cools, AR; Helfrich, SE; Spooren, WP | 1 |
| Filion, M; Matsumura, M; Richard, H; Tremblay, L | 1 |
| Chase, TN; Engber, TM; Mouradian, MM | 1 |
| Alp, MS; Aspey, BS; Harrison, MJ; Patel, Y | 1 |
| Blanchet, PJ; Chase, TN; Del Dotto, P; van den Munckhof, P; Verhagen Metman, L | 1 |
| Bhattacharya, S; Brooks, DJ; Bryant, DJ; Cox, IJ; Sargentoni, J; Seery, JP; Taylor-Robinson, SD; Turjanski, N | 1 |
| Brotchie, J; Ravenscroft, P | 1 |
| Coper, H; Lorenc-Koci, E; Ossowska, K; Pietraszek, M; Schulze, G; Smiałowska, M; Wardas, J; Wolfarth, S | 1 |
| Pollack, AE | 1 |
| Aizawa, H; Kwak, S; Mannen, T; Shibasaki, H; Shimizu, T | 1 |
| Meldrum, B | 1 |
| Baryshnikov, VA; Ermolina, LA; Turova, NF | 1 |
10 review(s) available for glutamic acid and Dyskinesia Syndromes
| Article | Year |
|---|---|
Roles of the M
Topics: Acetylcholine; Basal Ganglia; Cholinergic Neurons; Dopamine; Dystonia; Glutamic Acid; Humans; Interneurons; Molecular Targeted Therapy; Movement Disorders; Muscarinic Antagonists; Neostriatum; Parkinson Disease; Receptor, Muscarinic M4; Receptors, Dopamine; Synaptic Transmission | 2019 |
Consensus paper: pathological role of the cerebellum in autism.
Topics: Animals; Autistic Disorder; Cell Adhesion Molecules, Neuronal; Cerebellar Diseases; Cerebellum; Cognition Disorders; Disease Models, Animal; Extracellular Matrix Proteins; gamma-Aminobutyric Acid; Gene-Environment Interaction; Glutamic Acid; Humans; Magnetic Resonance Imaging; Mitochondria; Movement Disorders; Nerve Tissue Proteins; Neurotransmitter Agents; Oxidative Stress; Reelin Protein; Serine Endopeptidases | 2012 |
[Treatment of non-dopamine-dependent signs in parkinsonian syndromes: evaluation and results].
Topics: Anti-Dyskinesia Agents; Botulinum Toxins; Cholinesterase Inhibitors; Clozapine; Dementia; Depressive Disorder; Dopamine; Glutamic Acid; Humans; Movement Disorders; Parkinsonian Disorders; Selective Serotonin Reuptake Inhibitors; Serotonin; Synaptic Transmission; Treatment Outcome | 2003 |
Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations.
Topics: Ataxia; Attention Deficit Disorder with Hyperactivity; Environmental Pollutants; Epilepsy; Glutamic Acid; Humans; Infant, Newborn; Iron; Mercury; Movement Disorders; Multiple Sclerosis; Mutagens; Neostriatum; Nerve Growth Factors; Receptors, Dopamine | 2003 |
Cannabinoid control of motor function at the basal ganglia.
Topics: Animals; Basal Ganglia; Cannabinoid Receptor Modulators; Cannabinoids; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Motor Activity; Movement Disorders; Parkinson Disease; Receptor, Cannabinoid, CB1; Signal Transduction | 2005 |
Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.
Topics: Dopamine; Glutamic Acid; Humans; Movement Disorders; Parkinson Disease | 1996 |
Effects of combined glutamate and platelet-activating factor inhibition on the outcome of focal cerebral ischaemia - an initial screening study.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Drug Combinations; Glutamic Acid; Leucine; Male; Movement Disorders; Neuroprotective Agents; Periaqueductal Gray; Piperazines; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sodium Channel Blockers; Time Factors | 1997 |
NMDA receptors in the basal ganglia.
Topics: Basal Ganglia; Glutamic Acid; Humans; Huntington Disease; Movement Disorders; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 2000 |
Anatomy, physiology, and pharmacology of the basal ganglia.
Topics: Acetylcholine; Animals; Basal Ganglia; Cell Communication; Dopamine; Glutamic Acid; Humans; Movement Disorders; Neural Pathways | 2001 |
Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Basal Ganglia Diseases; Brain; Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Glutamates; Glutamic Acid; Humans; Huntington Disease; Mice; Movement Disorders; Nerve Degeneration; Neurotransmitter Agents; Parkinson Disease; Rats | 1985 |
29 other study(ies) available for glutamic acid and Dyskinesia Syndromes
| Article | Year |
|---|---|
Movement Disorder in Wilson Disease: Correlation with MRI and Biomarkers of Cell Injury.
Topics: Adolescent; Adult; Age of Onset; Biomarkers; Child; Cytokines; Disease Progression; Dyskinesias; Female; Glutamic Acid; Glutathione; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Male; Malondialdehyde; Movement Disorders; Neuroimaging; Oxidative Stress; Severity of Illness Index; Thiobarbituric Acid Reactive Substances; Young Adult | 2021 |
Neuropsychiatric Manifestations of Wilson Disease: Correlation with MRI and Glutamate Excitotoxicity.
Topics: Adolescent; Adult; Behavioral Symptoms; Brain Mapping; Cognition Disorders; Copper; Feeding and Eating Disorders; Female; Glutamic Acid; Hallucinations; Hepatolenticular Degeneration; Humans; Liver; Magnetic Resonance Imaging; Male; Mood Disorders; Movement Disorders; Neuroimaging; Neurotransmitter Agents; Quetiapine Fumarate; Severity of Illness Index; Young Adult | 2021 |
Pre-therapy Neural State of Bilateral Motor and Premotor Cortices Predicts Therapy Gain After Subcortical Stroke: A Pilot Study.
Topics: Aspartic Acid; Biomarkers; Female; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Motor Cortex; Movement Disorders; Outcome Assessment, Health Care; Pilot Projects; Stroke Rehabilitation | 2018 |
Blockade of Rapid Influx of Extracellular Zn
Topics: Animals; Behavior, Animal; Chelating Agents; Dopaminergic Neurons; Extracellular Space; Glutamic Acid; Male; Models, Biological; Movement Disorders; Nerve Degeneration; Paraquat; Parkinson Disease; Rats, Wistar; Reactive Oxygen Species; Substantia Nigra; Zinc | 2019 |
Limbic neurochemical changes in patients with functional motor symptoms.
Topics: Adult; Affective Symptoms; Anxiety; Case-Control Studies; Creatine; Depression; Female; Glutamic Acid; Glutamine; Humans; Limbic System; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Movement Disorders; Quality of Life; Severity of Illness Index | 2019 |
Involvement of astroglial glutamate-glutamine shuttle in modulation of the jaw-opening reflex following infraorbital nerve injury.
Topics: Animals; Astrocytes; Constriction, Pathologic; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Glutamate-Ammonia Ligase; Glutamic Acid; Jaw; Male; Mandibular Nerve; Maxillary Nerve; Methionine Sulfoximine; Movement Disorders; Muscle, Skeletal; Rats, Sprague-Dawley; Reflex; Skin Physiological Phenomena; Trigeminal Motor Nucleus | 2014 |
The effects of D-allose on transient ischemic neuronal death and analysis of its mechanism.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Analysis of Variance; Animals; Cerebral Cortex; Deoxyguanosine; Disease Models, Animal; DNA Damage; Drug Administration Schedule; Gerbillinae; Glucose; Glutamic Acid; Ischemic Attack, Transient; Lactic Acid; Male; Microdialysis; Movement Disorders; Neurons; Oxygen; Time Factors | 2014 |
Mice deficient in carbonic anhydrase type 8 exhibit motor dysfunctions and abnormal calcium dynamics in the somatic region of cerebellar granule cells.
Topics: Animals; Bicuculline; Biomarkers, Tumor; Calcium; Calcium Signaling; Central Nervous System Agents; Cerebellum; Cohort Studies; Electric Stimulation; GABA-A Receptor Antagonists; Glutamic Acid; Lactones; Learning; Mice, Inbred C57BL; Mice, Mutant Strains; Motor Activity; Movement Disorders; Nerve Tissue Proteins; Neurons; Rotarod Performance Test; Sesquiterpenes; Synaptic Transmission; Tissue Culture Techniques | 2015 |
Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
Topics: Animals; Animals, Newborn; Aquaporin 4; Astrocytes; Axons; Cells, Cultured; Cerebrospinal Fluid; Disease Models, Animal; Glial Fibrillary Acidic Protein; Glutamic Acid; Humans; Immunoglobulin G; Movement Disorders; Myelin Basic Protein; Myelin Sheath; Neuromyelitis Optica; Optic Nerve; Rats; Spinal Cord | 2016 |
Neuroprotective effects of intrastriatal injection of rapamycin in a mouse model of excitotoxicity induced by quinolinic acid.
Topics: Animals; Body Weight; Corpus Striatum; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Glutamic Acid; Male; Mice; Mice, Inbred C57BL; Movement Disorders; Nerve Degeneration; Neuroglia; Neurons; Neuroprotective Agents; Neurotoxicity Syndromes; Postural Balance; Potassium Chloride; Quinolinic Acid; Sirolimus; Synaptosomes | 2017 |
Two novel comments on the treatment of Huntington's disease.
Topics: Basal Ganglia; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Huntington Disease; Models, Neurological; Movement Disorders | 2009 |
Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis.
Topics: Animals; Antigens, CD; Corpus Striatum; Dendrites; Disease Models, Animal; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Glutamic Acid; Glycoproteins; In Vitro Techniques; Mice; Mice, Inbred C57BL; Movement Disorders; Myelin-Oligodendrocyte Glycoprotein; Neurons; Neuroprotective Agents; Patch-Clamp Techniques; Peptide Fragments; Physical Conditioning, Animal; Silver Staining; Statistics, Nonparametric; Synapses; Synaptic Potentials | 2009 |
Guanosine prevents thermal hyperalgesia in a rat model of peripheral mononeuropathy.
Topics: Analgesics; Animals; Central Nervous System; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Exploratory Behavior; Glutamic Acid; Guanosine; Hyperalgesia; Male; Movement Disorders; Pain Measurement; Pain Threshold; Rats; Rats, Wistar; Sciatica; Statistics, Nonparametric; Time Factors | 2010 |
Changes in D-aspartate ion currents in the Aplysia nervous system with aging.
Topics: Aging; Animals; Aplysia; Cells, Cultured; Cellular Senescence; D-Aspartic Acid; Ganglia, Invertebrate; Glutamic Acid; Ion Channels; Models, Animal; Movement Disorders; Nervous System Physiological Phenomena; Neurons; Receptors, N-Methyl-D-Aspartate | 2010 |
Compensatory molecular and functional mechanisms in nervous system of the Grm1(crv4) mouse lacking the mGlu1 receptor: a model for motor coordination deficits.
Topics: Animals; Brain; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Male; Mice; Mice, Inbred BALB C; Movement Disorders; Mutation; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Synaptosomes | 2013 |
Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Newborn; Anti-Anxiety Agents; Asphyxia Neonatorum; Behavior, Animal; Benzodiazepines; Cell Death; Epilepsy; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Hypoxia-Ischemia, Brain; Infant, Newborn; Male; Movement Disorders; Neostriatum; Neuroprotective Agents; Neurotoxins; Rats; Receptors, AMPA; Synaptic Transmission | 2002 |
Changes of mGluR4 and the effects of its specific agonist L-AP4 in a rodent model of diffuse brain injury.
Topics: Aminobutyrates; Animals; Behavior, Animal; Brain; Brain Injuries; Cell Count; Cognition Disorders; Diffuse Axonal Injury; Disease Models, Animal; Excitatory Amino Acid Agonists; Glutamic Acid; Male; Movement Disorders; Nerve Degeneration; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; RNA, Messenger; Synaptic Transmission; Treatment Outcome | 2003 |
Proton MR spectroscopy in succinic semialdehyde dehydrogenase deficiency.
Topics: Adult; Aldehyde Oxidoreductases; Amino Acid Metabolism, Inborn Errors; Brain; gamma-Aminobutyric Acid; Genes, Recessive; Glutamic Acid; Glutamine; Humans; Hydroxybutyrates; Magnetic Resonance Spectroscopy; Male; Movement Disorders; Predictive Value of Tests; Protons; Reference Values; Seizures; Speech Disorders; Succinate-Semialdehyde Dehydrogenase | 2004 |
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Denervation; Glutamic Acid; Levodopa; Male; Movement Disorders; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Subthalamic Nucleus; Sympatholytics; Synaptic Transmission | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; Disease Models, Animal; Disease Progression; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; Encephalomyelitis, Autoimmune, Experimental; Endocannabinoids; Exploratory Behavior; Furans; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamic Acid; Huntington Disease; Male; Malonates; Movement Disorders; Multiple Sclerosis; Nitro Compounds; Oxidopamine; Polyunsaturated Alkamides; Propionates; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2006 |
[Neurotransmission mechanism of movement disorders in multiple sclerosis].
Topics: Adolescent; Adult; Aspartic Acid; Disease Progression; Female; Glutamic Acid; Humans; Male; Middle Aged; Motor Activity; Movement Disorders; Multiple Sclerosis; Neuromuscular Junction; Severity of Illness Index; Synaptic Transmission | 2007 |
Kainate and glutamate neurotoxicity in dependence on the postnatal development with special reference to hippocampal neurons.
Topics: Age Factors; Animals; Glutamates; Glutamic Acid; Hippocampus; Injections, Intraventricular; Kainic Acid; Movement Disorders; Pyrrolidines; Rats; Rats, Inbred Strains; Seizures; Synaptic Transmission | 1984 |
Interactions of the subthalamic nucleus and the subpallidal area in oro-facial dyskinesia: role of GABA and glutamate.
Topics: Animals; Behavior, Animal; Cats; Facial Muscles; gamma-Aminobutyric Acid; Glutamic Acid; Hypothalamus; Male; Mouth; Movement Disorders; Picrotoxin; Thalamic Nuclei; Time Factors | 1995 |
Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum.
Topics: Action Potentials; Animals; Behavior, Animal; Bicuculline; Brain Mapping; Globus Pallidus; Glutamic Acid; Injections, Spinal; Macaca fascicularis; Movement Disorders; Time Factors | 1995 |
Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Dextromethorphan; Dextrorphan; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; Movement Disorders; Parkinson Disease; Psychomotor Performance; Receptors, N-Methyl-D-Aspartate | 1998 |
A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.
Topics: Aged; Aspartic Acid; Cerebral Cortex; Choline; Corpus Striatum; Creatine; Female; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Movement Disorders; Parietal Lobe; Parkinson Disease; Reference Values; Temporal Lobe | 1999 |
Decline in motor functions in aging is related to the loss of NMDA receptors.
Topics: Aging; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Ankle Joint; Biomarkers; Biomechanical Phenomena; Brain Mapping; Cell Count; Dizocilpine Maleate; Dopamine; Electromyography; Female; Glutamic Acid; Learning Disabilities; Maze Learning; Movement Disorders; Muscle, Skeletal; Nerve Tissue Proteins; Pliability; Psychomotor Performance; Raclopride; Rats; Rats, Wistar; Reaction Time; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
A case of adult onset pure pallidal degeneration. II. Analysis of neurotransmitter markers, with special reference to the termination of pallidothalamic tract in human brain.
Topics: Adult; Aged; Basal Ganglia Diseases; Biomarkers; Brain Chemistry; Choline O-Acetyltransferase; Female; gamma-Aminobutyric Acid; Globus Pallidus; Glutamates; Glutamic Acid; Humans; Male; Middle Aged; Movement Disorders; Nerve Degeneration; Neurotransmitter Agents; Norepinephrine; Thalamus | 1991 |
[Characteristics of the amino acid spectrum of the blood of children with intellectual deficiency].
Topics: Amino Acids; Ammonia; Arginine; Aspartic Acid; Child; Female; Glutamates; Glutamic Acid; Humans; Intellectual Disability; Male; Movement Disorders; Polyamines; Syndrome; Urea | 1986 |